Drug intelligence / Profile preview

Pro-Bone

Development stage: Phase 1
Lead developer: OsteoBuild
Modality: Small Molecules
Administration: Oral

Overview

Pro-Bone is an investigational drug developed by OsteoBuild Ltd. It functions as an Aquaporine-9 (AQ-9) channels inhibitor. By inhibiting AQ-9 channels, Pro-Bone is designed to ameliorate the bone degradation process, making it a potential treatment for conditions like osteopenia. It is administered orally as 500 mg capsules twice daily.

Brand names: Pro-boneTM

Targets

AQP9 (Aquaporin-9)

Beyond the preview

Go deeper on Pro-Bone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pro-Bone.

Explore the full profile